Difference between revisions of "Light-chain (AL) amyloidosis - null regimens"
Jump to navigation
Jump to search
m |
|||
| Line 27: | Line 27: | ||
<div class="toccolours" style="background-color:#cbd5e8"> | <div class="toccolours" style="background-color:#cbd5e8"> | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
| − | *[[#Melphalan_monotherapy.2C_then_auto_HSCT|High-dose melphalan with autologous hematopoietic stem cell transplant]] | + | *[[#Melphalan_monotherapy.2C_then_auto_HSCT|High-dose melphalan with autologous hematopoietic stem cell transplant]] consolidation |
</div></div> | </div></div> | ||
| + | |||
===References=== | ===References=== | ||
# '''NJCT-0703:''' Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, Zhang H, Liu Z. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014 Jan 6;12:2. [http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-12-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895846/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24386911/ PubMed] [https://clinicaltrials.gov/study/NCT01998503 NCT01998503] | # '''NJCT-0703:''' Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, Zhang H, Liu Z. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014 Jan 6;12:2. [http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-12-2 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895846/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24386911/ PubMed] [https://clinicaltrials.gov/study/NCT01998503 NCT01998503] | ||
Revision as of 00:03, 23 March 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main light-chain (AL) amyloidosis page for regimens that include active anticancer treatment.
First-line therapy (including transplant ineligible)
No induction
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Huang et al. 2014 (NJCT-0703) | 2009-2012 | Randomized Phase 2 (C) | BD | Seems to have inferior OS |
No induction prior to transplant.
Subsequent treatment
References
- NJCT-0703: Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, Zhang H, Liu Z. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014 Jan 6;12:2. link to original article link to PMC article PubMed NCT01998503
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kyle et al. 1978 | NR | Randomized (C) | MP | Shorter time on treatment |
No active antineoplastic treatment.
References
- Kyle RA, Greipp PR. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood. 1978 Oct;52(4):818-27. link to original article PubMed